Guardian Pharmacy sees FY24 revenue ~$1.228B, consensus $1.21B

FY24 revenue is expected to be approximately $1.228B, an expected increase of approximately 17.4% year-over-year, driven by organic growth of the business and the previously announced acquisitions of Heartland Pharmacy and Freedom Pharmacy, completed on April 1, 2024, and November 1, 2024, respectively. Revenue was also positively impacted by an increase in flu and COVID-19 vaccinations administered through clinics in certain long-term care facilities we serve. Net Income (loss) is expected to be between ($71.8M)-($72.8M), an expected decrease between $109.5M-$110.5M year-over-year, primarily attributable to approximately $131.5M of share-based compensation expense, the majority of which is associated with our Corporate Reorganization and initial public offering. This also resulted in a net loss per share for the year. Adjusted EBITDA is expected to be approximately $90.8M, an expected increase of approximately 19.2% year-over-year.